Programme 2020

Friday: September 11, 2020

10:00 (EST)

Introduction & Virtual Meeting Objectives
John Gribben


Session I: Hodgkin’s Lymphoma

Chairs: Peter Johnson & Pier Luigi Zinzani 

  • Early-stage unfavorable cHL; Peter Borchmann
  • KEYNOTE 204; Pier Luigi Zinzani
  • Hodgkin’s Lymphoma in the era of targeted therapy; Peter Johnson

Roundtable Discussion


Session II: Immunotherapy/Microenvironment

Chairs: David Maloney & Stephen Ansell

  • Crosstalk between lymphocytes and their microenvironment; Jan A. Burger
  • PRAME expression and the tumor microenvironment; Christian Steidl
  • CBT in specific lymphoma subtypes; Stephen Ansell

Roundtable Discussion


Session III: Novel Therapies Part I

Chairs: Laurie Sehn & John Gribben

  • Novel ADCs; Laurie Sehn
  • CD20 / CD3 bispecific antibodies: How to choose?; Martin Hutchings
  • Oral PI3K delta (δ) inhibitors in lymphoma; Jennifer Brown

Roundtable Discussion


Roundup of Day 1:
John Gribben, Stephen Ansell & Laurie Sehn

Saturday: September 12, 2020


Session IV: Novel Therapies Part II
Chairs: Laurie Sehn & John Gribben

  • Novel BTK inhibitors: how to choose?; Tom Witzig
  • SINE inhibitors: Selinexor; John Kuruvilla  
  • Tafasitamab (MOR208) in DLBCL; Gilles Salles

Roundtable Discussion


Session V: T-cell Therapies for Lymphoma

Chairs: Cath Bollard & Jeremy Abramson 

  • CD19-CAR-T cells; Jeremy Abramson
  • CD30, CD5 and/or 7 CAR-T cells; Cath Bollard
  • T cell-engaging therapies – BiTEs and beyond; Stephen Gottschalk 

Roundtable Discussion


Final Virtual Meeting Summary & Conclusions
iwNHL Scientific Committee

© 2014 - 2021 World Health Communications Ltd

Media Partner:

Meeting Organizers: